“Notwithstanding the ongoing competitive headwinds, that we continue to expect to extend through 2025, we remain very excited about the overall opportunity and future for cell therapy.”

In context

“r year, driven by higher average realized price and increased rest-of-world demand, partially offset by lower demand in the US. Sequentially, sales were down 1%, reflecting European pricing favorability in the prior quarter that did not repeat, partially offset by higher demand outside the US. Tecartus sales of $78 million were down 22% year over year and 20% sequentially, reflecting increased in and out of class competition. Our work to increase CAR T class penetration is ongoing, and we continue to make progress in breaking down barriers to adoption in the community setting, including in accreditation and commercial reimbursement. More broadly, we continue to raise awareness of the strength of our data, the advantages of a one-time treatment, and the potential benefits of earlier CAR T. Notwithstanding the ongoing competitive headwinds, that we continue to expect to extend through 2025, we remain very excited about the overall opportunity and future for cell therapy. The potential launch of anetocel in multiple myeloma in 2026, and exciting early-stage data in our next-generation products across lymphoma, and solid tumors at ASCO. Before I hand over to Dietmar, I'd like to thank the commercialization team for delivering a great start to the year. We remain focused on expanding the reach of our current portfolio but are also very excited about the rich pipeline of near-term launches over the next twelve to eighteen months. In addition to the ongoing launch of Libdelzi, and the potential launch of lenacapavir for PrEP in 2025, we are also looking forward to the potential launch of anetocel in multiple myeloma and Trodelvy in first-line metastatic triple-negative breast cancer in 2026. And with that, I'll hand the call over to Dietmar. Dietmar Berger: Th”